Valuation: NeoGenomics, Inc.

Market Cap 2.48B 2.18B 2.06B 1.88B 3.51B 238B 3.54B 24.63B 9.54B 122B 9.32B 9.12B 391B P/E 2026 *
-65.2x
P/E 2027 * -77.7x
Enterprise Value 2.48B 2.18B 2.06B 1.88B 3.51B 238B 3.54B 24.63B 9.54B 122B 9.32B 9.12B 391B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 2.81x
Free-Float
96.11%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-2.91%
Current month+7.93%
1 month+11.28%
3 months+36.41%
6 months+149.10%
Current year+64.37%
1 week 18.27
Extreme 18.27
20.05
1 month 16.86
Extreme 16.865
20.05
Current year 7.06
Extreme 7.065
20.05
1 year 7.06
Extreme 7.065
20.05
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Tax

General Counsel

-2,692 0.0021%
8/21/26 Exercice

Chairperson

67,272 0.0524%
8/4/26 Sell

Controller/Auditor

-20,000 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-2.91%+143.76%+57.03% 2.48B
+0.92%+11.69%+153.15%+817.41% 59.47B
+0.22%-3.45%+10.35%+50.78% 25.11B
-0.63%-2.34%-11.16%-38.35% 6.52B
-0.73%-6.86%-6.74%+154.37% 5.57B
-0.46%+2.92%+22.23%+61.31% 3.4B
-0.09%-12.56%-24.58%+2,376.19% 2.64B
+16.38%+1.68%+35.11%+45.42% 2.27B
+1.10%+4.93%+0.79%-53.43% 2B
-1.33%+9.36%+32.67%-11.94% 1.89B
Average +1.42%+0.36%+35.56%+345.88% 11.14B
Weighted average by Cap. +0.76%+4.97%+87.72%+512.61%

Financials

2026 *2027 *
Net sales 804M 706M 666M 607M 1.14B 77.07B 1.14B 7.97B 3.09B 39.37B 3.02B 2.95B 127B 885M 777M 733M 668M 1.25B 84.83B 1.26B 8.78B 3.4B 43.34B 3.32B 3.25B 139B
Net income -39.05M -34.27M -32.37M -29.49M -55.21M -3.74B -55.61M -387M -150M -1.91B -147M -143M -6.15B -32.73M -28.72M -27.12M -24.72M -46.27M -3.14B -46.6M -325M -126M -1.6B -123M -120M -5.15B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-09-25 US$19.33 -1.18% 2,019,688
26-09-24 US$19.56 +6.54% 2,948,600
26-09-23 US$18.36 -2.81% 2,911,516
26-09-22 US$18.89 -2.68% 4,000,684
26-09-21 US$19.41 -2.51% 1,435,170
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
19.33USD
Average target price
19.72USD
Spread / Average Target
+2.03%

Quarterly revenue - Rate of surprise